Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Original Research

Diagnostic Testing for Diabetes Using HbA1c in the Abu Dhabi Population

Weqaya: the Abu Dhabi Cardiovascular Screening Program

  1. Cother Hajat, MBBS, MPH, PHD, MRCP, MFPH1⇓,
  2. Oliver Harrison, MA, MBBS1 and
  3. Zaid Al Siksek, BSC, MHCA2
  1. 1Department of Public Health and Research, Health Authority, Abu Dhabi, United Arab Emirates
  2. 2Health Authority, Abu Dhabi, United Arab Emirates
  1. Corresponding author: Cother Hajat, chajat{at}haad.ae.
Diabetes Care 2011 Nov; 34(11): 2400-2402. https://doi.org/10.2337/dc11-0284
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Abstract

OBJECTIVE The validity of HbA1c as a population diagnostic tool was tested against oral glucose tolerance testing in Abu Dhabi nationals.

RESEARCH DESIGN AND METHODS The screening tool of HbA1c and random glucose was validated against the “gold standard” oral glucose tolerance test according to World Health Organization criteria.

RESULTS The HbA1c threshold of 6.4% provided the optimum balance between sensitivity (72.0%) and specificity (84.3%) with positive and negative predictive values of 47.9 and 93.7% and area under the receiver operating characteristics curve of 0.78. This threshold compares with a threshold of 6.5% recommended by the International Scientific Committee and American Diabetes Association and of 6.3% in a recent study in China.

CONCLUSIONS This study successfully validates the feasibility and threshold of HbA1c for diagnosis of diabetes at the population level in a Middle-Eastern population. This result is a major step in the fight to tackle the increasing burden of diabetes in the United Arab Emirates.

The United Arab Emirates (UAE) has been reported as having the second highest world prevalence of diabetes by the World Health Organization (2005) (1) and the International Diabetes Federation (2). The Weqaya program screened >92% of the UAE national population for cardiovascular disease risk factors including diabetes (3). The International Expert Committee on Diabetes (4) and the American Diabetes Association (5) recommended that an HbA1c threshold of 6.5% should be diagnostic of diabetes. This article seeks to determine the utility of HbA1c as a population-level diagnostic tool.

RESEARCH DESIGN AND METHODS

The Weqaya screening program commenced in April 2008 for UAE nationals (aged ≥18 years) residing in Abu Dhabi linked to the provision of free comprehensive health insurance (called Thiqa) (3). Individuals consented in line with the principles of the Abu Dhabi Medical Research Council (6). Further details about the screening program are described elsewhere (3), but in summary, it was conducted at a series of dedicated primary health care facilities with a systematic screening methodology (available at http://www.haad.ae/HAAD/LinkClick.aspx?fileticket=sj-gI8-BIv4%3d&tabid=820). Screening recorded demographics and self-reported indicators; anthropometric measures included waist-to-hip ratio, BMI, and a single-arterial blood pressure reading; and blood testing included nonfasting samples for glucose, LDL and HDL cholesterol, and HbA1c.

Patients at higher risk of having diabetes (HbA1c ≥6.1% or random glucose ≥11.1 mmol/L) or missing HbA1c and glucose data from the first round of screening were invited back for further investigation. Fasting glucose levels (12 h fasting), oral glucose tolerance test (OGTT) using a 75-g glucose load in line with World Health Organization guidelines (7), and HbA1c levels were recorded at follow-up. Only individuals attending public facilities were included to ensure standardized laboratory methods. HbA1c was measured on whole blood using the Cobas Integra Instrument in line with the National Glycohemoglobin Standardization Program, standardized to the Diabetes Control and Complications Trial reference assay (8).

Statistical analysis

All statistical analyses were conducted using STATA version 10.0 (STATACorp LP, College Station, TX). Continuous variables were compared using t tests for comparison of means. The screening test was HbA1c (ranging from 6.1 to 7%) and random glucose (≥11.1 mmol/L). The reference test was fasting and 2-h glucose after a 75-g glucose load. Diagnostic testing determined sensitivity, specificity, positive predictive value , and negative predictive value. The receiver operating characteristic (ROC) curve areas were determined to compare area under the curve (AUC) for sensitivity versus 1 − specificity.

RESULTS

A total of 1,028 subjects were included in this analysis. Mean (95% CI) for BMI and waist circumference were 30.4 kg/m2 (29.9–30.9) and 97 cm (95.8–98.1). Means for systolic blood pressure and diastolic blood pressure, LDL and HDL cholesterol, triglyceride, and fasting and 2-h postload glucose levels were within normal ranges.

HbA1c was diagnostic of diabetes using the American Diabetes Association criteria in 216 (21.0%) of the study sample.

Table 1 shows the sensitivity, specificity, positive predictive value, negative predictive value, and AUC for various thresholds of HbA1c against OGTT as the reference test. The results show that the HbA1c threshold of 6.4% had the highest AUC of 0.78 (95% CI 0.75–0.82) with sensitivity of 72% (65–78%) and specificity of 84% (82–87%). Using an HbA1c threshold of 6.4% to diagnose diabetes would have resulted in 72% of patients with diabetes being correctly diagnosed and 16% being incorrectly diagnosed.

View this table:
  • View inline
  • View popup
Table 1

Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the receiver operating characteristics curve comparing various thresholds of HbA1c with the WHO criteria for diabetes

A comparison of the study cohort with the full Weqaya cohort found higher mean age in this study at 42 years compared with 35 years (P < 0.001). Nondiabetic patients in this cohort had higher mean age, BMI, waist circumference, systolic blood pressure, diastolic blood pressure, and LDL cholesterol than nondiabetic patients from the Weqaya cohort. For diabetic patients, mean age and systolic blood pressure were lower in this cohort than in diabetic patients in the Weqaya cohort.

CONCLUSIONS

This is one of the first studies to demonstrate the utility of HbA1c for diagnosing diabetes and has shown that 6.4% is an optimum HbA1c threshold for the Abu Dhabi national population.

Use of HbA1c as a diagnostic tool

Studies repeatedly demonstrate that within populations, over one-third of all patients with diabetes remain undiagnosed, with resulting complications due to late diagnosis (9). The availability of a single nonfasting blood test could facilitate successful population-level screening programs. The Weqaya study demonstrated this.

HbA1c is an independent predictor of cardiovascular events in patients with diabetes and nondiabetic subjects (10), which makes HbA1c data from screening programs a valuable resource for public health planning.

Comparison with other studies

In this study, an HbA1c threshold of 6.4% yielded the highest AUC (0.78). A recent study in China comparing HbA1c screening with OGTT demonstrated sensitivity, specificity, and AUC of 63%, 96%, and 0.86, respectively (11). Sensitivities and specificities reported using fasting plasma glucose as the reference in the Chinese study were 56 and 97% for their optimum HbA1c threshold of 6.4% (11) and in National Health and Nutrition Examination Survey data were 59 and 97% for their optimum HbA1c threshold of 5.8% (12).

The higher sensitivity and lower specificity in the Weqaya study may be due to population factors affecting glycation of hemoglobin, such as hemoglobinopathies and other abnormal hemoglobin types, anemias (13), vitamins C and E, iron deficiency, and some medication use (14). Different ethnic groups have also been shown to have HbA1c levels up to 0.4–0.7% higher than Caucasian populations despite similar glucose levels (15).

Choice of HbA1c threshold

The choice of HbA1c threshold for clinical practice will depend on whether the tool is being used for screening or diagnosis. Screening tests usually warrant the choice of high sensitivity over specificity. Because HbA1c has now been recommended for use as a diagnostic test, specificity is increasingly important, and the threshold of 6.4% in this study provides a high specificity without too much compromise of sensitivity.

Strength and limitations

This study is the first in a Middle Eastern population to screen at population level using HbA1c and has been shown to be representative (3); however, some differences were shown in nondiabetic subjects between this study sample and the overall Weqaya population.

Summary

HbA1c has been validated as a suitable test for the definitive diagnosis of diabetes in the Weqaya population screening program in a high-risk Middle-Eastern population. This is a major step in the fight to tackle the increasing burden of diabetes in the UAE.

Acknowledgments

All authors were employees of the Health Authority, Abu Dhabi, for the duration of this study.

No potential conflicts of interest relevant to this article were reported.

C.H. designed the study, conducted data analysis and interpretation, and wrote the manuscript. O.H. and Z.A.S. contributed to the study design and review of the manuscript.

  • Received February 26, 2011.
  • Accepted August 19, 2011.
  • © 2011 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

References

  1. ↵
    WHO Statistical Information System (WHOSIS) data [Internet]. Available from http://apps.who.int/whosis/data. Accessed 6 January 2010
  2. ↵
    International Diabetes Federation. The Diabetes Atlas. 4th ed. [Internet], 2009. Available from http://atlas.idf-bxl.org. Accessed 6 January 2010
  3. ↵
    1. Hajat C,
    2. Harrison O
    . The Abu Dhabi Cardiovascular Program: the continuation of Framingham. Prog Cardiovasc Dis 2010;53:28–38pmid:20620423
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327–1334pmid:19502545
    OpenUrlFREE Full Text
  5. ↵
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl. 1):S62–S69pmid:20042775
    OpenUrlFREE Full Text
  6. ↵
    HAAD. 2010 Statistics Report [Internet], 2010. Available from www.HAAD.ae/statistics. Accessed 6 June 2011
  7. ↵
    World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation [Internet], 2006. Available from http://www.idf.org/webdata/docs/WHO_IDF_definition_diagnosis_of_diabetes.pdf. Accessed 6 January 2010
  8. ↵
    American Diabetes Association. Standards of medical care in diabetes: 2010. Diabetes Care 2010;33(Suppl. 1):S11–S61pmid:20042772
    OpenUrlFREE Full Text
  9. ↵
    1. Harris MI,
    2. Flegal KM,
    3. Cowie CC,
    4. et al
    . Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 1998;21:518–524pmid:9571335
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Selvin E,
    2. Steffes MW,
    3. Zhu H,
    4. et al
    . Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800–811pmid:20200384
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Bao Y,
    2. Ma X,
    3. Li H,
    4. et al
    . Glycated haemoglobin A1c for diagnosing diabetes in Chinese population: cross sectional epidemiological survey. BMJ 2010;340:c2249pmid:20478961
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Buell C,
    2. Kermah D,
    3. Davidson MB
    . Utility of A1C for diabetes screening in the 1999–2004 NHANES population. Diabetes Care 2007;30:2233–2235pmid:17563338
    OpenUrlFREE Full Text
  13. ↵
    1. Saudek CD,
    2. Derr RL,
    3. Kalyani RR
    . Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA 2006;295:1688–1697pmid:16609091
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Saudek CD,
    2. Herman WH,
    3. Sacks DB,
    4. Bergenstal RM,
    5. Edelman D,
    6. Davidson MB
    . A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab 2008;93:2447–2453
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Ziemer DC,
    2. Kolm P,
    3. Weintraub WS,
    4. et al
    . Glucose-independent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies. Ann Intern Med 2010;152:770–777pmid:20547905
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Diabetes Care: 34 (11)

In this Issue

November 2011, 34(11)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Diagnostic Testing for Diabetes Using HbA1c in the Abu Dhabi Population
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Diagnostic Testing for Diabetes Using HbA1c in the Abu Dhabi Population
Cother Hajat, Oliver Harrison, Zaid Al Siksek
Diabetes Care Nov 2011, 34 (11) 2400-2402; DOI: 10.2337/dc11-0284

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Diagnostic Testing for Diabetes Using HbA1c in the Abu Dhabi Population
Cother Hajat, Oliver Harrison, Zaid Al Siksek
Diabetes Care Nov 2011, 34 (11) 2400-2402; DOI: 10.2337/dc11-0284
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Original Research

  • Association of Early-Phase In-Hospital Glycemic Fluctuation With Mortality in Adult Patients With Coronavirus Disease 2019
  • The SEE Study: Safety, Efficacy, and Equity of Implementing Autonomous Artificial Intelligence for Diagnosing Diabetic Retinopathy in Youth
  • Risk of Blindness Among Patients With Diabetes and Newly Diagnosed Diabetic Retinopathy
Show more Original Research

Epidemiology/Health Services Research

  • Health Care Use and Costs in Individuals With Diabetes With and Without Comorbid Depression in Germany: Results of the Cross-sectional DiaDec Study
  • Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
  • Exercise During the First Trimester of Pregnancy and the Risks of Abnormal Screening and Gestational Diabetes Mellitus
Show more Epidemiology/Health Services Research

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.